Precision therapeutics for major unmet medical needs
About Us
Changing the way we treat disease
We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact. Find out more about the SPRING trial for P. gingivalis positive Alzheimer's disease.
News & Events
Lighthouse Pharma’s Dr. Michael J. Detke to Spotlight Novel Alzheimer’s Approach in National BrightFocus Event
Dr. Detke, will be featured in the upcoming BrightFocus Foundation “Zoom In on Dementia & Alzheimer’s: Clinical Research” event on April 2, 2026 Register Here.
​
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025
​
Lighthouse Pharmaceuticals Relocates Headquarters to the Buck Institute for Research on Aging
​
Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs
​
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-Positive Alzheimer’s Disease
Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor
Lighthouse Pharmaceuticals Initiates Phase 2 SPRING Trial of LHP588 in P. gingivalis-Positive Alzheimer’s Disease
48-Week Study to Evaluate the Safety and Efficacy of Oral LHP588 Dosed Once Daily
